Structure and biological activity of pathogen-like synthetic nanomedicines

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue 4, 2012, Pages 497-506

  Lorincz, Orsolya ^a   Toke, Eniko R ^a   Somogyi, Eszter ^a   Horkay, Ferenc ^b   Chandran, Preethi L ^b   Douglas, Jack F ^c   Szebeni, János ^d   Lisziewicz, Julianna ^a,e  

^a Genetic Immunity Kft   (Hungary)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY   (United States)

^d BAY ZOLTÁN NONPROFIT LTD FOR APPLIED RESEARCH   (Hungary)

^e Genetic Immunity LLC   (United States)

Author keywords

DermaVir; Immunity; Immunotherapy; Vaccine

Indexed keywords

ATOMIC FORCE; CLINICAL DEVELOPMENT; DERMAVIR; ENDOSOMES; IMMUNE RESPONSE; IMMUNITY; IMMUNOTHERAPY; INFECTED CELLS; INTRACELLULAR STABILITY; MODE OF ACTION; NANOMEDICINES; POLYMER SURFACES; POLYPLEXES; SHELF LIFE; SPHERICAL VIRUS; STRUCTURAL STABILITIES; TEMPERATURE INFLUENCE;

ANTIGENS; ATOMIC FORCE MICROSCOPY; BIOACTIVITY; IMMUNOLOGY; NANOPARTICLES; NUCLEIC ACIDS; SPHERES; STABILITY; VACCINES; VIRUSES;

MEDICAL NANOTECHNOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NUCLEIC ACID; PLASMID DNA; POLYETHYLENEIMINE; SODIUM CHLORIDE;

ABSORPTION; ARTICLE; ATOMIC FORCE MICROSCOPY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG STABILITY; ENDOSOME; IMMUNE RESPONSE; NANOMEDICINE; PH; PHYSICAL CHEMISTRY; SHELF LIFE; STRUCTURE ACTIVITY RELATION; SURFACE PROPERTY; TEMPERATURE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; CELL LINE; CELL NUCLEUS; DNA; HIV-1; HUMANS; NANOPARTICLES; PARTICLE SIZE; TRANSFECTION;

EID: 84860238423     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.07.013     Document Type: Article

References (40)

1. Garcea R.L., Gissmann L. Virus-like particles as nanomedicines and vessels for the delivery of small molecules. Curr Opin Biotechnol 2004, 15:513-517.
2. Jeong J.H., Sung W.K., Park T.G. Molecular design of functional polymers for gene therapy. Prog Polym Sci 2007, 32:1239-1274.
3. Zuber G., Dauty E., Nothisen M., Belguise P., Behr J.P. Towards synthetic viruses. Adv Drug Deliv Rev 2001, 52:245-253.
4. Lobo B.A., Koe G., Smith J.G., Middaugh C.R. Isothermal titration calorimetric analysis of the interaction between cationic lipids and plasmid DNA. Arch Biochem Biophys 2001, 386:95-105.
5. Zuidam N.J., Barenholz Y. Electrostatic and structural properties of complexes involving plasmid DNA and cationic lipids commonly used for gene delivery. Biochim Biophys Acta 1998, 1368:115-128.
6. Kleeman E., Dailey L.A., Abdelhady H.G., Gessler T, Schmehl T, et al. Modified polyethylenimines as non-viral gene delivery systems for aerosol gene therapy: investigations of the complex structure and stability during air-jet and ultrasonic nebulization. J Control Release 2004, 100:437-450.
7. Demeneix B., Behr J., Boussif O., Zanta M.A., Abdallah B., Remy J. Gene transfer with lipospermines and polyethylenimines. Adv Drug Deliv Rev 1998, 30:85-95.
8. Sternberg B., Sorgi F.L., Huang L. New structures in complex formation between DNA and cationic liposomes visualized by freeze-fracture electron microscopy. FEBS Lett 1994, 356:361-366.
9. Toke E.R., Lorincz O., Somogyi E., Lisziewicz J. Rational development of a stable liquid formulation for nanomedicine products. Int J Pharm 2010, 392:261-267.
10. Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc Natl Acad Sci 1995, 92:7297-7301.
11. Lisziewicz J., Gabrilovich D.I., Varga G., Xu J., Greenberg P.D., Arya S.K., et al. Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells. J Virol 2001, 75:7621-7628.
12. Lisziewicz J., Trocio J., Whitman L., Varga G., Xu J., Bakare N., et al. DermaVir: a novel topical nanomedicine for HIV/AIDS. J Invest Dermatol 2005, 124:160-169.
13. Irache J.M., Salman H.H., Gamazo C., Espuelas S. Mannose-targeted systems for the delivery of therapeutics. Expert Opin Drug Deliv 2008, 5:703-724.
14. Lisziewicz J., Trocio J., Xu J., Whitman L., Ryder A., Bakare N., et al. Control of viral rebound through therapeutic immunization with DermaVir. AIDS 2005, 19:35-43.
15. Lori F., Trocio J., Bakare N., Kelly L.M., Lisziewicz J. DermaVir, a novel HIV immunization technology. Nanomedicine 2005, 23:2030-2034.
16. Lisziewicz J., Calarota S., Banhegyi D., Lisziewicz Z., Ujhelyi E., Lori F. Single DermaVir Patch treatment of HIV+ individuals induces long-lasting, high-magnitude, and broad HIV-specific T cell responses 2008.
17. van Lunzen J., Pollard R., Stellbrink H.J., Plettenberg A., Nátz E., Lisziewicz Z., et al. DermaVir for initial treatment of HIV-infected subjects demonstrates preliminary safety, immunogenicity and HIV-RNA reduction versus placebo immunization 2010.
18. Natz E., Lisziewicz J. Rational design of formulated DNA vaccines: the DermaVir approach. Gene vaccines 2011, 127-143. Springer-Verlag, Vienna. J. Thalhamer (Ed.).
19. Somogyi E., Xu J., Gudics A., Tóth J., Kovács A.L., Lori F., et al. A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIV. Vaccine 2011, 29:744-753.
20. Zékány L., Nagypál I. Computation methods for the determination of formation constants 1991, Plenum Press, New York.
21. Szebeni J., Muggia F.M., Alving C.R. Complement activation by cremophor el as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998, 90:300-306.
22. Szebeni J., Fontana J.L., Wassef N.F., Mongan P.D., Morse D.S., et al. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs. Circulation 1999, 99:2302-2309.
23. Wan L., You T., Zou Y., Oupický D., Mao G. DNA release dynamics from bioreducible poly(amino amine) polyplexes. J Phys Chem B 2009, 113:13735-13741.
24. Lamaze C., Dujeancourt A., Baba T., Lo C.G., Benmerah A., Dautry-Varsat A., et al. Interleukin 2 receptors and detergent-resistant membrane domains define a clathrin-independent endocytic pathway. Mol Cell 2001, 7:661-671.
25. Bruewer M., et al. Interferon-gamma induces internalization of epithelial tight junction proteins via a macropinocytosis-like process. FASEB J 2005, 19:923-933.
26. Srinivasachari S., Liu Y., Prevette E.L., Reineke T.M. Trehalose click polymers inhibit nanoparticle aggregation and promote pDNA delivery in serum. J Am Chem Soc 2006, 128:8172-8184.
27. Han X., et al. The heterogeneous nature of polyethylenimine-DNA complex formation affects transient gene expression. Cytotechnology 2009, 60:63-75.
28. Hughes M.E., Brandin E., Golovchenko J.A. Optical absorption of DNA-carbon nanotube structures. Nano Lett 2007, 7:1191-1194.
29. Park J.J., Weiger M.C., De Paoli Lacerda S.H., Pristinski D., Becker M.L., Douglas J.F., et al. Characterization of non-equilibrium nanoparticle adsorption on a model biological substrate. Langmuir 2010, 26:4822-4830.
30. Bloomfield V.A., Criothers D.M., Tinoco I. Nucleic acids: structure, properties and functions 2000, University Science Books, Sausalito (Ca).
31. Tomac S., Sarkar M., Ratilainen T., Wittung P., Nielsen P.E., Nordén B., et al. Ionic effects on the stability of peptide nucleic acid (PNA) complexes. J Am Chem Soc 1996, 118:5544-5552.
32. Akinc A., Thomas M., Klibanov A.M., Langer R. Exploring polyethyleneimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med 2005, 7:657-663.
33. Godbey W.T., Kenneth K.W., Mikos A.G. Tracking the intracellular path of poly(ethyleneimine)/DNA complexes for gene delivery. Proc Natl Acad Sci 1999, 96:5177-5181.
34. Suh J., Wirtz D., Hanes J. Efficient active transport of gene nanocarriers to the nucleus. Proc Natl Acad Sci 2003, 100:3878-3882.
35. Plank C., Mechtler K., Szoka F.C., Wagner E. Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum Gene Ther 1996, 7:1437-1446.
36. Merkel O.M., Zheng M., Mintzer M.A., Pavan G.M., Librizzi D., Maly M., et al. In vitro and in vivo complement activation and related anaphylactic effects associated with polyethyleneimine-graft-poly(ethyleneglycol) block copolymers. Biomaterials 2011, 32:4936-4942.
37. Szebeni J., Baranyi L., Savay S., Lutz H.U., Jelezarova E., Bunger R., et al. The role of complement activation in hypersensitivity to pegylated liposomal doxorubicin (Doxil). J Liposome Res 2000, 10:467-481.
38. Chanan-Khan A., Szebeni J., Savay S., Liebes L., Rafique N.M., Alving C.R., et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol 2003, 14:1430-1437.
39. Schaffer D.V., Fidelman N.A., Dan N., Lauffenburger D.A. Vector unpacking as a potential barrier for receptor-mediated polyplex gene delivery. Biotechnol Bioeng 2000, 67:598-606.
40. Eliyahu H., Siani S., Azzam T., Domb A.J., Barenholz Y. Relationship between chemical composition, physical properties and transfection efficiency of polysaccharide-spermine conjugates. Biomaterials 2006, 27:1646-1655.